2348 — Dawnrays Pharmaceutical (Holdings) Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.76bn
- HK$343.19m
- CNY1.06bn
- 70
- 93
- 77
- 94
Annual balance sheet for Dawnrays Pharmaceutical (Holdings), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 932 | 786 | 993 | 1,067 | 1,365 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 331 | 368 | 403 | 322 | 268 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,549 | 1,511 | 1,744 | 1,720 | 2,202 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 782 | 1,143 | 1,308 | 1,225 | 1,236 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,904 | 3,340 | 3,673 | 3,623 | 4,009 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 480 | 697 | 932 | 669 | 555 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 733 | 959 | 1,031 | 768 | 685 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,171 | 2,381 | 2,642 | 2,855 | 3,324 |
| Total Liabilities & Shareholders' Equity | 2,904 | 3,340 | 3,673 | 3,623 | 4,009 |
| Total Common Shares Outstanding |